KAT8 and plasma cell myeloma: It upregulated KAT8 and the histone methyltransferase EZH2 in H929 and RPMI8226 myeloma cells, enhancing H4K16ac and H3K27me3 levels in the microtubule-associated protein 1 light chain 3 beta (MAP1LC3B/LC3B) promoter, enhancing LC3B transcription, activating autophagy, and inhibiting myeloma proliferation [128].